Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 23 of the 24 references it cites were found in a registry or an index.

Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study

Abstract

Background: Guidelines recommend selective serotonin reuptake inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) as first-line treatments for major depressive disorder (MDD) and emphasize the importance of early pharmacological treatment as key factors to treatment success. Objectives: To compare the MDD-related healthcare resource utilization (HCRU) and cost among patients (1) with early vs late pharmacological treatment initiation and (2) achieving minimum therapeutic dose (MTD) early vs late. Methods: The MarketScan database (2010-2015) was used. Adults who were newly-treated with SSRI/SNRI within 12 months after the initial MDD diagnosis (index) were included. Patients who initiated SSRI/SNRI within 2 weeks of the index date were defined as early initiators; those who reached MTD within 4 weeks of index date were defined as early MTD achievers. MDD-related HCRU and costs per year after the index date were compared between early and late initiators and between early and late achievers using propensity score matching and generalized linear models. Results: Of the 55,539 patients, 60% were early initiators and 61% were early MTD achievers. The mean number of MDD-related outpatient visits per year were significantly higher for late initiator (6.7 vs 4.2, p p Conclusions: There is an opportunity to improve outcomes by treating MDD patients with SSRI/SNRI within 2 weeks and at or above the MTD within 4 weeks of diagnosis or less.

Overview

Integrity signals

Registry

Crossref · 10.1080/03007995.2019.1652053

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 24 references

Research works printed but not linked: 2

  1. WHO, 2008, The global burden of disease: 2004 update
  2. 10.1080/00031305.1985.10479383 · doi:10.1080/00031305.1985.10479383 · Paper page

Cited by

See all 15

Metadata

Authors
McIntyre, R. S., Prieto, R., Schepman, P., Yeh, Y.-C., Boucher, M., Shelbaya, A., Chambers, R., Gao, X., & Pappadopulos, E.
Affiliations
  • University Health Network (CA)
  • Saint Louis University (ES)
  • Pfizer (United States) (US)
  • Pharmerit (United States) (US)
  • Pfizer (Canada) (CA)
Corresponding author
McIntyre, Roger S.
Venue
Current Medical Research and Opinion
Published
2019-09-16
Volume
35
Issue
12
Pages
2169-2177
ISSN
  • 0300-7995 (ISSN-L)
  • 1473-4877
OpenAlex
W2965680320
Cited by
15
References
24
Citations by year
2026: 3 · 2025: 3 · 2024: 2 · 2023: 5 · 2021: 2
FWCI
0.31
Type
journal article
Language
en
Open access
closed
Locations
  • Current Medical Research and Opinion (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Mental Health Treatment and Access
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
Keywords
major depressive disorder, selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, treatment initiation timing, healthcare resource utilization, health care costs, outpatient visits, antidepressant prescribing
MeSH terms
Serotonin and Noradrenaline Reuptake Inhibitors, Adult, Antidepressive Agents, Cost-Benefit Analysis, Major Depressive Disorder, Depressive Disorder, Major, Female, Humans, Male, United States, Health Care Rationing, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Early Medical Intervention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. https://app.cochat.ai/papers/10.1080/03007995.2019.1652053
The paper
McIntyre, R. S., Prieto, R., Schepman, P., Yeh, Y.-C., Boucher, M., Shelbaya, A., Chambers, R., Gao, X., & Pappadopulos, E. (2019). Healthcare resource use and cost associated with timing of pharmacological treatment for major depressive disorder in the United States: a real-world study. Current Medical Research and Opinion. https://doi.org/10.1080/03007995.2019.1652053

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.